Guggenheim initiated coverage on shares of Metsera (NASDAQ:MTSR – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $56.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 105.81% from the company’s previous close.
Several other research analysts also recently commented on MTSR. Evercore ISI assumed coverage on shares of Metsera in a report on Tuesday. They set an “outperform” rating for the company. Bank of America began coverage on Metsera in a research report on Tuesday. They issued a “buy” rating and a $38.00 target price on the stock.
View Our Latest Analysis on Metsera
Metsera Stock Performance
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
- Five stocks we like better than Metsera
- Health Care Stocks Explained: Why You Might Want to Invest
- Buffett’s on the Sidelines – Should You Follow?
- What is a support level?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- How to trade using analyst ratings
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
